Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | CFTR | P13569 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18863815 | 1.00 | GAA (0.59) | GAACA12CA1CA2CA7 | |
| SCHEMBL2701033 | 0.90 | GAA (0.61) | GAACA12CA1CA2CA7 | |
| SCHEMBL1538335 | 0.85 | CA12 (0.63) | GAACA12CA1CA2CA7 | |
| SCHEMBL2242907 | 0.85 | KDM4E (0.51) | GAACA12CA1CA2CA7 | |
| SCHEMBL3974563 | 0.83 | GAA (0.54) | GAACA12CA1CA2CA7 | |
| SCHEMBL31430552 | 0.83 | GAA (0.63) | GAACA12CA1CA2CA7 | |
| SCHEMBL27268313 | 0.83 | ABL1 (0.57) | GAACA12CA1CA2CA7 | |
| SCHEMBL19833958 | 0.83 | GAA (0.50) | GAACA12CA1CA2CA7 | |
| SCHEMBL31430590 | 0.83 | GAA (0.50) | GAACA12CA1CA2CA7 | |
| SCHEMBL29906742 | 0.83 | GAA (0.50) | GAACA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087635-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025050125-A1 | SUBSTITUTED BENZOXAZOLYLAMINO BENZOXAZOLES | IMMVENTION THERAPEUTIX (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-113365995-B | Immunomodulators, compositions and methods thereof | 贝达药业股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-115677689-B | Polysubstituted benzene PD-L1 inhibitor, composition and application thereof | 杭州和正医药有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112424194-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4223369-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4141002-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11572366-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| CN-115677689-A | Polysubstituted benzene PD-L1 inhibitor, composition and application thereof | 杭州和正医药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-110267953-B | Tetrahydroimidazo [4,5-C ] pyridine derivatives as inducers of PD-L1 internalization | 因赛特公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-109641885-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-3377488-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3558990-B1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORP (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114249726-A | Biphenyl compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2022022600-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572366-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | GAA 2040/4885CA12 2505/4885CA1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.